Your browser doesn't support javascript.
loading
Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.
Ohwada, Chikako; Sakaida, Emiko; Takeda, Yusuke; Doki, Noriko; Igarashi, Aiko; Onizuka, Makoto; Toyosaki, Masako; Tanaka, Masatsugu; Tachibana, Takayoshi; Kataoka, Keisuke; Kato, Jun; Fujisawa, Shin; Kato, Seiko; Nakasone, Hideki; Naganuma, Ken; Saitoh, Takayuki; Shono, Katsuhiro; Hagihara, Maki; Saito, Takeshi; Usuki, Kensuke; Mori, Takehiko; Nakaseko, Chiaki; Okamoto, Shinichiro; Kanda, Yoshinobu.
Afiliação
  • Ohwada C; Department of Hematology, International University of Health and Welfare, Narita City, Chiba, 286-8520, Japan. cohwada@iuhw.ac.jp.
  • Sakaida E; Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Takeda Y; Department of Hematology, Chiba University Hospital, Chiba, Japan.
  • Doki N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Igarashi A; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Onizuka M; Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.
  • Toyosaki M; Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.
  • Tanaka M; Department of Hematology and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Tachibana T; Department of Hematology and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Kataoka K; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kato J; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Fujisawa S; Department of Hematology, Yokohama City University Medical Center, Kanagawa, Japan.
  • Kato S; Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Nakasone H; Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
  • Naganuma K; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
  • Saitoh T; Department of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan.
  • Shono K; Department of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
  • Hagihara M; Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Kanagawa, Japan.
  • Saito T; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Usuki K; Department of Hematology, NTT Medical Center, Tokyo, Japan.
  • Mori T; Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Nakaseko C; Department of Hematology, International University of Health and Welfare, Narita City, Chiba, 286-8520, Japan.
  • Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Kanda Y; Division of Hematology, Jichi Medical University, Tochigi, Japan.
Int J Hematol ; 2024 Jul 17.
Article em En | MEDLINE | ID: mdl-39017858
ABSTRACT
A prospective multicenter observational study of organ response was conducted in patients with chronic GVHD diagnosed by the NIH criteria. When response was assessed at 12 months (12 M) in 118 patients, 74.6% were classified as responders and 25.4% as non-responders. The skin and oral cavity were the most frequent organs used as the basis for determining overall response. The lungs, liver, and eyes were also used in 20% of patients. Non-response decisions at 12 M were most frequent in the lungs. A significantly higher percentage of responders than non-responders completed systemic treatment (24.3% vs. 3.3%, P = 0.02). Global scoring showed significant changes, with improvement in responders and worsening in non-responders throughout the observation period. Two-year transplant-related mortality, using the 12 M assessment as the landmark, was significantly worse in non-responders (28.5% vs. 2,7%, P = 0.0001), while the 2-year recurrence rate was equivalent (5.4% vs. 4.8%, P = 0.78). Consequently, the 2-year overall survival rate from the 12 M assessment was significantly better in responders than non-responders (95% vs. 65.3%, P = 0.0001). Our data suggests that patients who do not achieve a response within the first year should be candidates for clinical studies on chronic GVHD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article